- Home
- CALC vs GRCE Comparison
CALC vs GRCE Comparison
Compare CALC & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- GRCE
- Stock Information
- Founded
- CALC 2011
- GRCE 2002
- Country
- CALC United States
- GRCE United States
- Employees
- CALC N/A
- GRCE N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- GRCE
- Sector
- CALC Health Care
- GRCE
- Exchange
- CALC Nasdaq
- GRCE NYSE
- Market Cap
- CALC 22.9M
- GRCE 42.1M
- IPO Year
- CALC N/A
- GRCE N/A
- Fundamental
- Price
- CALC $1.61
- GRCE $3.13
- Analyst Decision
- CALC Strong Buy
- GRCE Strong Buy
- Analyst Count
- CALC 3
- GRCE 1
- Target Price
- CALC $16.33
- GRCE $12.00
- AVG Volume (30 Days)
- CALC 29.8K
- GRCE 55.7K
- Earning Date
- CALC 08-11-2025
- GRCE 06-23-2025
- Dividend Yield
- CALC N/A
- GRCE N/A
- EPS Growth
- CALC N/A
- GRCE N/A
- EPS
- CALC N/A
- GRCE N/A
- Revenue
- CALC N/A
- GRCE N/A
- Revenue This Year
- CALC N/A
- GRCE N/A
- Revenue Next Year
- CALC N/A
- GRCE N/A
- P/E Ratio
- CALC N/A
- GRCE N/A
- Revenue Growth
- CALC N/A
- GRCE N/A
- 52 Week Low
- CALC $1.42
- GRCE $1.75
- 52 Week High
- CALC $5.97
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- CALC 46.35
- GRCE N/A
- Support Level
- CALC $1.42
- GRCE N/A
- Resistance Level
- CALC $1.85
- GRCE N/A
- Average True Range (ATR)
- CALC 0.15
- GRCE 0.00
- MACD
- CALC -0.00
- GRCE 0.00
- Stochastic Oscillator
- CALC 41.86
- GRCE 0.00
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.